NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes
20 Septembre 2022 - 7:00AM
NorthStar Medical Radioisotopes and IBA Sign Agreement for Two
Additional Rhodotron® Electron Beam Accelerators for Commercial
Production of Radioisotopes
NorthStar is further expanding commercial-scale
domestic radioisotope production capabilities using IBA’s
environmentally preferable Rhodotron® accelerator technology
Louvain-La-Neuve, Belgium, and BELOIT,
Wisconsin, USA September 20, 2022 – IBA
(Ion Beam Applications S.A., EURONEXT), the world leader in
particle accelerator technology, and NorthStar Medical
Radioisotopes, LLC, a global innovator in the development,
production and commercialization of radiopharmaceuticals used for
medical imaging and therapeutic applications, today announced a new
agreement under which NorthStar will purchase two additional
Rhodotron® TT300 HE electron beam accelerators, and the associated
beamlines, from IBA for the production of molybdenum-99
(Mo-99).
The purchase marks a total of five Rhodotron®
accelerators that NorthStar has purchased from IBA to date.
NorthStar previously purchased two electron beam accelerators from
IBA in 2019 for the production of Mo-99, and purchased a third
accelerator in 2021 for production of the therapeutic radioisotope
actinium-225 (Ac-225). The additional accelerators will be used to
further expand NorthStar’s commercial-scale radioisotope production
capabilities at its Beloit, Wisconsin headquarters. All NorthStar
production processes employ innovative, environmentally preferable
technology and are non-uranium based.
NorthStar’s first Accelerator Production
facility expansion in Beloit is nearing completion and moving to
the final phase of activities required for licensure and FDA
approval. Both accelerators are operating at full power and
undergoing final testing. Equipment in the adjacent Isotope
Processing facility has been installed and undergoing final
testing. Construction of NorthStar’s dedicated Actinium-225
Production facility is also well underway, with shipment of the
third IBA Rhodotron® accelerator expected by the end of 2022.
“NorthStar continues to invest in the future of
nuclear medicine using innovative technology to advance
environmentally sustainable radioisotope production, and the
purchase of these additional accelerators marks another milestone
of our highly productive relationship with IBA,” said
Stephen Merrick, Chief Executive Officer of NorthStar.
“IBA has demonstrated extensive commercial expertise and excellent
performance in delivering electron beam accelerators for our Mo-99
production expansion program, and in the design and custom-build of
our Ac-225 accelerator. We are proud that IBA is a partner in
helping to make these important diagnostic imaging and therapeutic
radioisotope products available to advance patient health, and look
forward to continuing to work with them.”
Olivier Legrain, Chief Executive Officer
of IBA commented, “We are delighted to sign this latest
agreement with NorthStar Medical Radioisotopes and to continue to
deliver innovative solutions for reliable radioisotope supply.
IBA’s Rhodotron® accelerators provide the most advanced electron
accelerator technology in the world, enabling a non-uranium based
and highly efficient method for producing medical radioisotopes
such as Mo-99, Ac-225 and Cu-67. We look forward to continuing to
work with NorthStar to advance research and help patients.”
***ENDS***
About IBAIBA (Ion Beam
Applications S.A.) is the world leader in particle accelerator
technology. The company is the leading supplier of equipment and
services in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA is also a
leading player in the fields of industrial sterilization,
radiopharmaceuticals and dosimetry. The company, based in
Louvain-la-Neuve, Belgium, employs approximately 1,600 people
worldwide. IBA is a certified B Corporation (B Corp) meeting the
highest standards of verified social and environmental
performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA:
Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com.
About NorthStar Medical Radioisotopes,
LLC (NorthStar)NorthStar Medical Radioisotopes is a
commercial-stage nuclear medicine company that manufactures and
distributes diagnostic and therapeutic radioisotopes and
radiopharmaceuticals. The Company’s proprietary state-of-the-art
technology and proven management team have propelled it to the
forefront of U.S. medical radioisotope production as the sole
domestic producer of the diagnostic imaging radioisotope
molybdenum-99 (Mo-99). Mo-99 is used to generate technetium-99m
(Tc-99m), the standard of care in diagnostic imaging to assess the
extent and severity of heart disease and cancer. NorthStar’s unique
Mo-99 production process is non-uranium based and environmentally
friendly. NorthStar is expanding its industry-leading position in
the emerging area of therapeutic radioisotopes, which are used in
targeted radiopharmaceutical therapy to treat cancer, respiratory
and other diseases. Using first-in-kind and environmentally-sound
electron accelerator technology, NorthStar is poised to be the
first commercial-scale producer of therapeutic radioisotopes
actinium-225 (Ac-225) and copper-67 (Cu-67). NorthStar also
collaborates with other companies in the development of
radiopharmaceuticals. For more information about NorthStar’s
comprehensive radiopharmaceutical portfolio, visit:
www.northstarnm.com.
CONTACTS
IBASoumya ChandramouliChief
Financial Officer+32 10 475
890investorrelations@iba-group.com Olivier
LechienCorporate Communication Director+32 10 475
890communication@iba-group.com Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com |
For
NorthStar Medical Radioisotopes, LLC
Corporate:Lisa HolstVice President Sales and
Marketing678-471-9027
lholst@northstarnm.com Investor Relations:Paul
EstremExecutive Vice President and Chief Financial
Officer608-987-8318pestrem@northstarnm.com
Media:Priscilla
Harlan781-799-7917pharlan@shiningrockllc.com
|
- 20220920-NorthStar-IBA_2_accelerators_EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024